At Manchester Weight Loss Clinic, we’re always on the lookout for breakthroughs in safe, medically supported weight loss treatments. One of the most exciting developments on the horizon is Amycretin, a new weight loss pill that Manchester residents may be hearing more about in the near future. Developed by Novo Nordisk, the same pharmaceutical company behind Wegovy and Ozempic, Amycretin is showing incredibly promising results in early clinical trials.
Although it’s not yet available to the public, the science behind Amycretin—and the remarkable results seen so far—suggests this could be a major advancement in the fight against obesity and type 2 diabetes.
What Is Amycretin?
Amycretin is a dual-action weight loss drug currently being studied as a weekly injectable, with future trials planned for oral administration. Like Wegovy and Ozempic, Amycretin works by influencing key hormones that regulate appetite and blood sugar levels, but it goes a step further by targeting two specific receptors instead of just one.
The drug activates:
-
GLP-1 (glucagon-like peptide-1) receptors, which slow digestion, reduce appetite, and support blood sugar control
-
Amylin receptors, which help regulate satiety and complement the effects of GLP-1
By targeting both pathways simultaneously, Amycretin aims to reduce hunger more effectively and lead to more sustained weight loss, while also offering benefits for people with elevated blood sugar levels.
What the Research Says
A recent study published in The Lancet involved 125 adults who were administered weekly injections of Amycretin over a 36-week period. Participants receiving the highest dosage of 60mg lost an average of 24.3% of their body weight—a result that exceeds many currently available medical weight loss treatments, including semaglutide-based medications.
This kind of weight reduction not only improves physical appearance and energy levels but also significantly lowers the risk of developing type 2 diabetes, heart disease, high blood pressure, and joint-related conditions.
In addition to weight loss, the study noted improvements in blood glucose control, suggesting that Amycretin may also be suitable for those with prediabetes or existing metabolic issues.
Is Amycretin Available Yet?
Unfortunately, no, not yet. Amycretin is still in the clinical trial phase, and it’s not currently licensed for use in the UK. However, Novo Nordisk has announced that they are extremely encouraged by the initial findings. They plan to conduct further long-term studies to assess the drug’s safety profile, its long-term efficacy, and the feasibility of developing an oral form of the medication.
If future trials prove successful, Amycretin could become an important option for those who have struggled with other weight loss interventions or who are unable to tolerate existing medications like Wegovy.
How Amycretin Differs from Wegovy
Both Wegovy and Amycretin are being developed by Novo Nordisk, but they work slightly differently. While Wegovy (semaglutide) acts on the GLP-1 receptor only, Amycretin engages two hormonal systems—GLP-1 and amylin—potentially delivering more powerful appetite control and metabolic support.
This multi-targeted approach may be especially useful for people who:
-
Have previously plateaued on single-agent medications
-
Experience persistent hunger despite reduced food intake
-
Are managing both obesity and blood sugar irregularities
As more data emerges, we’ll learn whether Amycretin can offer broader or more sustained results than its predecessors.
What It Means for Weight Loss Patients in Manchester
If you’re actively seeking medical help to lose weight, you may be wondering how this new drug fits into your future. While Amycretin is not yet available, it represents a major step forward in pharmaceutical weight loss support. At Manchester Weight Loss Clinic, we’ll be closely following its development and updating our patients as it progresses through trials and into potential approval.
In the meantime, we continue to offer proven, licensed weight loss options, including:
-
GLP-1 receptor agonists like Wegovy (subject to availability and clinical assessment)
-
Nutritional support and behaviour change guidance
-
In-depth consultations to tailor treatment plans to your individual health and goals
We’re also happy to answer questions about emerging treatments like Amycretin, so that you’re informed and ready when the time comes.
Explore Your Personal Weight Loss Pathway
The question on many people’s minds right now is whether there’s a new weight loss pill Manchester residents should be aware of—and the answer is yes, but not just yet. Amycretin is shaping up to be an exciting development in the world of obesity treatment, offering greater results and more targeted appetite control than we’ve seen before.
At Manchester Weight Loss Clinic, we are committed to offering the latest evidence-based treatments and staying ahead of medical advancements. If you’re struggling to lose weight and need clinical support, we’re here to help guide you through the options currently available, with an eye on promising developments like Amycretin in the future. Reach out today.
Book a consultation today to explore your personalised path to safe, effective weight loss, with the support of a trusted clinic that’s with you every step of the way.
This blog was written on behalf of Manchester Weight Loss Clinic by Pharmacy Mentor.